Abstracts

Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance

Treatment regimens containing the NS5A inhibitors (NS5AI) ledipasvir (LDV) and ombitasvir (OBV) are approved for the treatment of HCV genotype 1 (GT1) infection. Overall, GT1b infected individuals have better treatment responses to NS5AI-containing regimens than GT1a infected individuals. Previous studies have demonstrated that the presence of NS5AI resistance-associated variants (RAVs) may impact treatment outcome. We…

Does Pulse-Wave Velocity Normalize With Increasing Time on ART? Evidence From CHER

Cross-sectional evidence strongly suggests increased prevalence of vascular disease in HIV+ children on antiretroviral therapy (ART) after adjusting for traditional atherosclerosis risk factors. Vascular abnormalities are typically associated with advanced HIV disease and with ART, particularly lopinavir/ritonavir (LPVr). Thus far, pediatric studies have focused on children initiating ART much later than 3 months of age.…

Changes in CVD Risk Factors With Early and Deferred ART in the START Trial

HIV infection and certain antiretroviral medications appear to contribute to cardiovascular disease (CVD) risk.  CVD events were similar between the early (at CD4 >500cells/µL) and deferred (to CD4 160mg/dL or use of lipid lowering drug), diabetes (diagnosis or fasting blood glucose ≥126 mg/dL) and hypertension (diagnosis or use of blood pressure medication) during follow-up were…

Cardiovascular Biomarkers After Switch to ABC/DTG/3TC: The STRIIVING Study

Improvements in inflammatory biomarker profiles have been documented in virologically-suppressed patients switching from PI and/or NNRTI to RAL and EVG. Because improvements in chronic inflammation may affect mortality and co-morbid disease development, we evaluated the effects of switch to ABC/DTG/3TC on markers of inflammation and immune activation. Participants were randomized 1:1 to switch to ABC/DTG/3TC…

Resistance Associated Variants: Data From the NIAID SYNERGY Trial

Treatment of chronic hepatitis C (HCV) has rapidly evolved from modestly-effective interferon-based regimens to highly effective, all oral, interferon-free directly acting antiviral (DAA) therapy. While DAAs are increasingly used for treatment of HCV worldwide, the impact of emerging resistance is largely unknown. In this study, we evaluated the role of baseline, treatment-emergent and treatment-enriched resistance…

Cardiovascular Risk Profile of Abacavir and Tenofovir Independent of HIV Infection

Observational and clinical studies suggest that abacavir sulphate (ABC), a component of antiretroviral therapy (ART) may be associated with a reversible increased risk of myocardial infarction (MI) and increased platelet aggregation in HIV positive patients. It is not clear whether increased cardiovascular risk is driven pharmacologically by ABC or pathophysiologically by HIV and co-morbidities. Since…